The implantation of an occluder in the left atrial appendage (LAA) is an emerging therapy for the treatment of patients suffering from atrial fibrillation and with a contraindication to oral anticoagulation. The LAA occluder (LAAO) provides a reduction of the potential risk of strokes by thromboembolism. Currently, only a few CE-approved devices are available on the market and the number of clinical trials is comparatively low. Furthermore, there is currently no standardized test method available for testing functionality of the occluder, especially for testing safe anchorage and permeability. Therefore, the aim of this study is to establish an in vitro test method to prove anchorage mechanism and permeability regarding thromboembolism of the LAAO under physiological conditions. A standardized technical and fully parameterized silicone model of a LAA, based on studies of different morphologies and sizes, was developed. The LAA model was mounted onto the left atrial chamber of a commercial pulse duplicator system to simulate physiological hemodynamic conditions. The test was performed using the Watchman device (Boston Scientific, USA; size: 31 mm). The inner implantation diameter of the LAA model was designed according to a target compression of 10% for the Watchman device in the implanted configuration. Furthermore, thrombus-like particles (n=150, d=1,7±0,05 mm) were added to represent the flushing of thrombi out of the LAA after device implantation. Within several cycles it was confirmed that no particles were washed out of the LAA model with the implanted occluder leading to a full protection against thromboembolism. It could also be shown that the occluder is firmly anchored in the LAA. Pressure measurements with sensors in the left atrium and in the LAA distal to the occluder could also show that the occluder has no influence on the pressure conditions in the LAA.
Introduction
The third most frequent cause of death in Germany is stroke with a mortality rate of 8% [1] . The main source of risk is thromboembolism in the left atrial appendage (LAA). Thromboembolism occurring in the left atrium has its origin in the left atrial appendage in 90% of cases [2] . Although oral anticoagulation with blood-thinning medications is the most common therapy option for preventing strokes, it also means that there is a burden of lifelong medication use. Some patients cannot even be treated with oral anticoagulation because it is contraindicated. For this reason, the minimally invasive implantation of a percutaneous LAA occluder is becoming increasingly relevant. Compared to pharmalogical therapy procedures, interventional therapy has superiority in the risk of bleeding and is at the same level with regard to stroke prophylaxis [3] . Typically an LAA occluder consists of a Nitinol stent structure sealed with a semi-permeable membrane to prevent thromboembolism. At the same time, the existing blood flow through the membrane has to be ensured. There are currently only a few CE approved LAA occluder on the European market available and the number of clinical studies is comparatively low [4] [5] [6] . The market leader is the Watchman LAA occluder, which currently represents the only device approved by the Food and Drug Administration (FDA) that is available on the US market. The Watchman LAA occluder consists of a nitinol stent which is covered with a polyethylene terephthalate membrane with a pore size of 160 µm. The occluder is currently available in different sizes (21, 24, 27, 30 and 33 mm) and is selected according to the size of the ostium diameter. In addition to the Watchman, there are other devices such as the LAA Amplatzer Amulet, the Lambre LAA Closure System and the Occlutech Device commercially available on the European market. There is currently no standardized test method available for testing the functionality of newly developed occluder devices, in particular for testing the safe anchorage of the occluder in the LAA but also for characterizing para-device leakage.
The aim of this study is to establish an in vitro test method to prove anchorage mechanism and protective effect of LAA occluder and prototypes against thromboembolism under physiological conditions. 
Materials and methods
To characterize an occluder under physiological test conditions, a standardized technical and fully parameterized model of a left atrial appendage was first developed based on studies of different morphologies and sizes. The classification of different morphologies was performed by Wang et al. in a study on the pre-interventional planning of an LAA occlusion, which resulted in four different morphologies: Chicken-Wing (48%), Cactus (30%), Windsock (19%) and Cauliflower (3%) [7] . Based on these results, DiBiase et al. conducted a further study on the correlation between LAA morphologies and stroke risks in patients with atrial fibrillation. It has been shown that chicken-wing morphology is the most common morphology. Nevertheless, the prevalence of pre-procedure stroke is the most common in cauliflower morphology (18%) (cactus: 12%, chicken-wing: 4%, windsock: 10%). In combination the Windsock morphology, which is the second most common morphology, has a 4.5 times higher prevalence of strokes compared to the chicken-wing morphology [8] . For this reason, the windsock morphology was chosen in relation to the morphologies that occur.
The geometry of the LAA is therefore geometrically described by a truncated cone shown in Figure 1 . The diameter at the ostium of the LAA is d=27 mm. This corresponds to a 10% compression of the occluder used in this test. The fluid volume, which is located in the LAA, was adapted according to the investigations of Ernst et al. and amounts to 12 ml [9] . Accordingly, the height of the truncated cone is 45 mm. In order to implement the LAA model into the left atrium of the Pulse Duplicator system, a sealing ring was also constructed on the LAA. To ensure the physiological conditions, the LAA model is integrated into the left atrial chamber of a pulse duplicator system (ViVitro Labs Inc., Victoria, BC, Canada). As mitral valve a mechanical valve prothesis (Björk Shiley) was used in the measurements as well as a pericardium TAVI-Prototype as the aortic valve. The complete test assembly is shown in Figure 3 . The left atrium, the left ventricle and the aortic valve of the pulse duplicator are shown. The enlarged section also shows the technical model of the LAA with the implanted occluder device. The occluder device is a Watchman LAA occluder developed by Boston Scientific with a diameter of D = 30 mm. To determine pressure also in the LAA, a pressure sensor was attached to the distal end of the LAA, so that pressure can be measured before the LAA in the left atrium, as well as the pressure in the LAA. For in vitro measurements under physiological test conditions some parameters have been selected which are listed in Table 1 . The test parameters were selected on the basis of the test conditions for aortic valve prostheses. After implanting the Watchman occluder into the LAA, spherical solid particles were added to the LAA to detect peri-device leakage or small particles flushed out of the LAA. The spherical solid particles were intended to represent the potential blood clots in the LAA. The number of particles added was 150 with a size of 1.5 mm ± 0.2 mm.
Results
The occluder device implanted in the LAA was examined under physiological conditions for its firm anchorage, proximal and distal pressure fluctuations and safety against flushing out thrombus-like particles. For this purpose, the device was subjected to several cardiological cycles and the movement of the device was examined in the technical model of the LAA. The distance between the anchoring struts and the ostium of the LAA model was measured immediately after implantation of the occluder and after the test cycles. The occluder in the LAA model before and after the in vitro test is shown in Figure 4 . It was found that the occluder is firmly anchored in the LAA model and no movement occurred after the number of cycles performed. In addition, the influence of the occluder on the pressure in the LAA was investigated. The pressure in the LAA was measured with and without an occluder device and averaged over ten cardiological cycles. The differences between the pressure change within one cycle in the LAA in the pulse duplicator system (blue) and the pressure in the LAA with implanted occluder device (red) are shown in Figure 5 . It can be seen that the implanted occluder causes only minimal changes in the pressure course in the LAA. The pressure with the occluder device is slightly lower over the entire cycle compared to the LAA without the occluder device. Due to the probably increased flow resistance in the LAA caused by the occluder, there is a minimal increased pressure gradient between the atrium and the LAA. As well as the pressure in the LAA, pressure was also measured in the atrium and ventricle during the cycle. The pressure diagrams for ventricular pressure (yellow), atrial pressure (blue) and LAA pressure (red) with implanted occluder are shown in Figure 6 . The diagram shows that the atrium pressure and the LAA pressure have similar progressions. Figure 6 : Representation of the pressure plot, measured in the pulse duplicator system, for the ventricular pressure (yellow), the pressure in the left atrium (blue) and the pressure in the LAA (orange) over the duration of a cardiological cycle.
It can also be seen that the pressure gradient proximal and distal to the device is minimally and the pressure in the LAA is continuously below the pressure in the atrium.
Furthermore, thrombus-like particles (n=150, d=1.7±0.05 mm) were added to the LAA model to visualize the wash out of thrombi from the LAA after implantation of the occluder device and to identify peri-device leakages. After several cycles, the number of particles in the LAA was re-recorded and it was found that no particles were washed out of the LAA model by peri-deivce leakages. Accordingly, it can be concluded that the occluder with the membrane has a comprehensive protective effect against thromboembolism.
Conclusion
With the development of a new technical LAA model and the implementation of this model into an already existing pulse duplicator system, allowing in vitro tests to be performed under physiological conditions, a new approach to testing occluder devices could be found.
A safe anchorage of the occluder in the LAA model could be tested under dynamic flow conditions. A comparison showed that no movement or translational displacement of the device occurs in the LAA. In addition, it could be shown that an implanted occluder has only a minor influence on the pressure conditions in the LAA. Finally, by adding thrombotic particles, it was determined that no particles were washed out of the LAA model even after several cycles with the implanted occluder. The implantation of the Watchman occluder therefore provided protection against thromboembolism.
Nevertheless, in vitro testing of an occluder device can still be further developed. For example, further LAA models are being developed with regard to their morphology in order to investigate their influence on the anchoring strength. The geometry of the implantation plane is to play a special role here. In addition, further particles of different sizes are to be added to the LAA. The aim is to investigate the minimum size at which particles can be washed out despite the protective effect of the occluder.
